Vertex Pharmaceuticals (VRTX) reachead $495.29 at the closing of the latest trading day, reflecting a +1.42% change compared to its last close.

Vertex Pharmaceuticals (VRTX) concluded the recent trading session at $502.92, signifying a +1.51% move from its prior day's close.

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...

Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an ...

Google Cloud's Vertex AI Search for Healthcare tool is designed to make it faster for healthcare professionals and other ...

Remarkable technological advancements have shaped the history of medicine for over 150 years. Historical breakthroughs have ...

For current and former smokers, statins may reduce the amount of chest muscle loss, while aspirin may contribute to increased chest muscle loss, according to a new study.

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...